India is the world’s largest supplier of generic medicines, accounting for 20% of global exports by volume. The sector plays a vital role in global health, supplying affordable drugs to developing countries as well as advanced markets like the U.S. and Europe. But the industry faces new challenges as regulators demand higher quality and compliance standards.
Hyderabad, often called “Pharma City,” is home to hundreds of manufacturers that produce generics and active pharmaceutical ingredients (APIs). Indian firms supply everything from antibiotics and vaccines to cancer drugs, often at prices far lower than branded equivalents. This makes them essential to health systems worldwide.
Quality and compliance are now top priorities. U.S. FDA inspections and WHO prequalification have become benchmarks for export access. Indian companies are investing heavily in upgrading facilities, implementing digital quality control, and training staff to meet evolving standards. The government is also pushing regulatory harmonization to make it easier for firms to enter new markets.
At the same time, supply chain resilience has become a concern. The COVID-19 pandemic exposed India’s reliance on Chinese raw materials. To address this, the government launched a Production Linked Incentive (PLI) scheme to boost domestic API production and reduce vulnerability.
Opportunities are growing in Africa and Latin America, where demand for affordable generics is surging. Indian firms are forming joint ventures and local manufacturing partnerships to deepen market presence. The rise of biosimilars also presents a new frontier for Indian pharma.
With its scale, expertise, and cost advantage, India’s generic industry remains globally competitive. But sustained leadership will depend on maintaining high standards and diversifying supply chains.
